Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsShares IssuedShares Outstanding
Ratios

Insight Molecular Diagnostics (IMDX) Accumulated Depreciation & Amortization: 2020-2023

Historic Accumulated Depreciation & Amortization for Insight Molecular Diagnostics (IMDX) over the last 4 years, with Sep 2023 value amounting to $404,000.

  • Insight Molecular Diagnostics' Accumulated Depreciation & Amortization rose 3.32% to $404,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $1.7 million, marking a year-over-year increase of 31.95%. This contributed to the annual value of $1.5 million for FY2022, which is 87.50% up from last year.
  • Per Insight Molecular Diagnostics' latest filing, its Accumulated Depreciation & Amortization stood at $404,000 for Q3 2023, which was down 7.13% from $435,000 recorded in Q2 2023.
  • In the past 5 years, Insight Molecular Diagnostics' Accumulated Depreciation & Amortization ranged from a high of $450,000 in Q1 2023 and a low of -$4.2 million during Q3 2020.
  • Moreover, its 3-year median value for Accumulated Depreciation & Amortization was $384,000 (2022), whereas its average is $322,818.
  • Data for Insight Molecular Diagnostics' Accumulated Depreciation & Amortization shows a peak YoY surged of 137.19% (in 2022) over the last 5 years.
  • Over the past 4 years, Insight Molecular Diagnostics' Accumulated Depreciation & Amortization (Quarterly) stood at -$4.0 million in 2020, then spiked by 105.39% to $218,000 in 2021, then spiked by 83.49% to $400,000 in 2022, then climbed by 3.32% to $404,000 in 2023.
  • Its Accumulated Depreciation & Amortization stands at $404,000 for Q3 2023, versus $435,000 for Q2 2023 and $450,000 for Q1 2023.